Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) Receives Consensus Rating of "Moderate Buy" from Brokerages

Key Points

• Analyst sentiment is moderately bullish: Enanta Pharmaceuticals has a consensus “Moderate Buy” rating, with five buy recommendations and one sell rating. The average 12-month price target is $21, compared with a recent share price of $12.
• Recent financial results fell short of expectations: The company reported a quarterly loss of $0.67 per share versus the expected loss of $0.51, while revenue of $14.36 million missed the $16.76 million consensus estimate.
• Institutional ownership remains high: Hedge funds and other institutional investors own approximately 94.99% of ENTA shares, with several firms adding or initiating positions during the second quarter.

Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA - Get Free Report) has earned an average rating of "Moderate Buy" from the six ratings firms that are covering the firm, MarketBeat Ratings reports. One research analyst has rated the stock with a sell recommendation and five have given a buy recommendation to the company. The average 12-month target price among brokers that have issued a report on the stock in the last year is $21.00.

ENTA has been the topic of a number of recent analyst reports. HC Wainwright reiterated a "buy" rating and issued a $20.00 target price on shares of Enanta Pharmaceuticals in a research note on Wednesday. Weiss Ratings reissued a "sell (d-)" rating on shares of Enanta Pharmaceuticals in a research report on Friday, July 17th. Finally, Wall Street Zen cut Enanta Pharmaceuticals from a "hold" rating to a "sell" rating in a research report on Saturday, August 22nd.

Enanta Pharmaceuticals Stock Up 0.4%

Shares of Enanta Pharmaceuticals stock opened at $12.00 on Friday. The firm has a market cap of $349.50 million, a price-to-earnings ratio of -4.98 and a beta of 0.93. The business has a 50-day moving average price of $13.19 and a 200-day moving average price of $13.32. Enanta Pharmaceuticals has a twelve month low of $7.05 and a twelve month high of $17.15.

Enanta Pharmaceuticals (NASDAQ:ENTA - Get Free Report) last released its quarterly earnings data on Monday, August 10th. The biotechnology company reported ($0.67) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.51) by ($0.16). Enanta Pharmaceuticals had a negative return on equity of 61.84% and a negative net margin of 96.89%.The firm had revenue of $14.36 million during the quarter, compared to the consensus estimate of $16.76 million. On average, equities analysts expect that Enanta Pharmaceuticals will post -2.36 EPS for the current fiscal year.

Institutional Inflows and Outflows

Several institutional investors have recently bought and sold shares of ENTA. Wellington Management Group LLP increased its holdings in Enanta Pharmaceuticals by 8.9% in the second quarter. Wellington Management Group LLP now owns 81,633 shares of the biotechnology company's stock valued at $1,190,000 after buying an additional 6,673 shares in the last quarter. Bank of America Corp DE acquired a new stake in shares of Enanta Pharmaceuticals in the second quarter worth approximately $314,000. Jupiter Topco LLC acquired a new stake in Enanta Pharmaceuticals during the 2nd quarter worth $53,252,000. ADAR1 Capital Management LLC purchased a new stake in Enanta Pharmaceuticals during the 2nd quarter valued at about $19,603,000. Finally, Legal & General Group Plc purchased a new stake in shares of Enanta Pharmaceuticals in the second quarter valued at approximately $41,000. 94.99% of the stock is currently owned by hedge funds and other institutional investors.

Enanta Pharmaceuticals Company Profile

Enanta Pharmaceuticals, Inc is a biotechnology company focused on discovering and developing small-molecule therapies for viral infections and other diseases. The company's research has primarily centered on antiviral medicines, including treatments for respiratory syncytial virus (RSV), hepatitis B, and other infectious diseases.

Enanta is best known for its role in the development of glecaprevir, a protease inhibitor used with pibrentasvir in AbbVie's Mavyret (also marketed as Maviret) treatment for chronic hepatitis C virus infection.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.